



NUCLEABIOMARKERS

Contact: Patrick J. Muraca, President and CEO

PRESS RELEASE

Nuclea Biomarkers, LLC
105 South Street
Pittsfield, MA 01201
Phone 413-749-4705
Fax: 413-445-9930
Email: pr@nucleabiomarkers.com
www.nucleabiomarkers.com

FOR IMMEDIATE RELEASE

NUCLEA BIOMARKERS ESTABLISHES RESEARCH COLLABORATION WITH DANA FARBER CANCER INSTITUTE CENTER FOR MOLECULAR ONCOLOGIC PATHOLOGY

Research to be conducted in DFCI's Center for Molecular Oncologic Pathology

Pittsfield, Massachusetts ----- March 1st, 2007 Nuclea Biomarkers, LLC

announced today that it has established a research collaboration with the DFCI's Center for Molecular Oncologic Pathology. The Agreement establishes a framework for the continued collaboration for research activities for the purpose of developing a database of prognostic/predictive biomarkers from an IHC survey of tumor microarrays.

“Nuclea continues it's mission to develop new biomarkers, to help support and provide funds to DFCI,” states Patrick Muraca, President and CEO. “

The term of the collaboration between Nuclea Biomarkers and DFCI is for a specified period of time with an option to renew the agreement.

Nuclea Biomarkers, LLC - Nuclea Biomarkers, LLC is a biotechnology services company that has developed a novel technology platform to improve greatly the efficiency of drug discovery research. Using the Company's extensive database of [genetic, molecular, outcomes...] data and data-mining services, research professionals in pharmaceutical and life sciences companies are able to focus time and money on the most promising paths for diagnosing and treating a broad range of diseases.

Dana Farber Cancer Institute - The mission of Dana-Farber Cancer Institute is to provide expert, compassionate care to children and adults with cancer while advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases.